Form 4: CFO Edgemond Exercises Options, Sells UTHR Shares

United Therapeutics CFO James Edgemond exercised 21,000 stock options and subsequently sold 21,000 common shares under a pre-arranged 10b5-1 plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock.
• On November 24, 2025, Edgemond exercised 21,000 stock options at an exercise price of $146.03 per share.
• Following the option exercise, his direct beneficial ownership of common stock increased to 29,142 shares (from an implied 8,142 shares prior to exercise).
• On the same day, he sold a total of 21,000 shares of common stock in multiple transactions.
• The sales occurred at weighted average prices ranging from $467.3519 to $482.2947 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 5, 2025.
• After these transactions, Edgemond's direct beneficial ownership of common stock is 8,142 shares.
• He also retains beneficial ownership of 517 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sell) under a pre-arranged plan. While a sale reduces insider holdings, the pre-planned nature mitigates negative sentiment, and it's a common way for executives to realize value from compensation.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider trading.
• The exercise price of the options ($146.03) is significantly lower than the sale prices (ranging from $467.3519 to $482.2947), indicating a substantial gain for the insider.

Negatives

• An insider selling a significant number of shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, suggesting a desire to diversify or realize gains.
• The sale of 21,000 shares represents a reduction in the CFO's direct common stock holdings from 29,142 to 8,142 shares, a decrease of approximately 72% of the shares held after the option exercise.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports routine insider transactions (option exercise and share sale) and does not provide information directly related to broader industry trends or competitive landscape. Such transactions are common for executives managing their equity compensation.

Comparison to Industry Standards

• This Form 4 reports an insider transaction, which is a standard disclosure requirement.
• The execution of transactions under a Rule 10b5-1 plan is a common practice among executives to manage personal finances while adhering to insider trading regulations.
• No specific comparable companies, projects, or results are relevant for this type of filing.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO could be interpreted in various ways, from routine financial planning to a signal of reduced confidence, though the 10b5-1 plan mitigates the latter. The overall impact is likely minimal given the pre-planned nature.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report. The reporting person will continue to hold 8,142 common shares and 517 stock options.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where the CFO exercised stock options and subsequently sold an equivalent number of shares. While it reduces the insider's direct common stock holdings, the transaction was executed under a Rule 10b5-1 plan, which suggests it's part of a personal financial management strategy rather than a reaction to new, undisclosed negative information. Such transactions are common for executives realizing value from their compensation. Therefore, this filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it doesn't alter the fundamental investment thesis for UTHR.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, CFO, Share Sale, Beneficial Ownership